Sei Investments Co. Has $5.44 Million Stake in Alkermes plc $ALKS

Sei Investments Co. lowered its position in Alkermes plc (NASDAQ:ALKS) by 19.3% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 153,817 shares of the company’s stock after selling 36,900 shares during the period. Sei Investments Co.’s holdings in Alkermes were worth $5,439,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also modified their holdings of the company. Norges Bank bought a new stake in Alkermes during the 4th quarter worth approximately $54,442,000. Baker BROS. Advisors LP raised its position in Alkermes by 23.7% in the 4th quarter. Baker BROS. Advisors LP now owns 10,012,267 shares of the company’s stock valued at $280,143,000 after purchasing an additional 1,920,916 shares during the last quarter. UBS Group AG raised its position in Alkermes by 237.4% in the 4th quarter. UBS Group AG now owns 2,544,895 shares of the company’s stock valued at $71,206,000 after purchasing an additional 1,790,729 shares during the last quarter. First Trust Advisors LP boosted its stake in Alkermes by 104.2% in the first quarter. First Trust Advisors LP now owns 2,968,785 shares of the company’s stock worth $104,976,000 after purchasing an additional 1,514,783 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in Alkermes by 32.0% in the fourth quarter. JPMorgan Chase & Co. now owns 5,184,547 shares of the company’s stock worth $145,064,000 after purchasing an additional 1,256,377 shares in the last quarter. 95.21% of the stock is owned by institutional investors and hedge funds.

Alkermes Stock Up 0.3%

NASDAQ ALKS opened at $49.67 on Wednesday. The stock has a fifty day moving average of $48.74 and a 200-day moving average of $38.51. The stock has a market capitalization of $8.33 billion, a P/E ratio of 130.71 and a beta of 0.34. Alkermes plc has a 52 week low of $25.17 and a 52 week high of $55.67. The company has a debt-to-equity ratio of 0.82, a quick ratio of 1.85 and a current ratio of 2.30.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Mizuho increased their target price on Alkermes from $53.00 to $65.00 and gave the stock an “outperform” rating in a report on Thursday, July 2nd. UBS Group upped their price target on shares of Alkermes from $42.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, May 6th. Weiss Ratings lowered shares of Alkermes from a “hold (c+)” rating to a “hold (c)” rating in a report on Monday, May 11th. Stifel Nicolaus restated a “buy” rating and issued a $63.00 price objective (up from $45.00) on shares of Alkermes in a research report on Monday, July 20th. Finally, HC Wainwright reaffirmed a “neutral” rating on shares of Alkermes in a research note on Thursday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $54.56.

Alkermes News Roundup

Here are the key news stories impacting Alkermes this week:

• Positive Sentiment: Analysts maintain a generally favorable view of Alkermes, with the stock receiving a consensus rating of “Moderate Buy.” The broader analyst coverage includes several Buy or Overweight ratings, supporting investor confidence in the company’s outlook. Alkermes Receives Consensus Recommendation of Moderate Buy
• Neutral Sentiment: HC Wainwright issued an estimate for Alkermes’ third-quarter earnings, giving investors another reference point ahead of the results. The specific forecast was not provided, so the direct earnings implication remains unclear. HC Wainwright Estimates Alkermes’ Q3 Earnings
• Negative Sentiment: Director Nancy Lynn Md Snyderman sold 44,472 ALKS shares for approximately $2.24 million, reducing her direct ownership by about 74%. The unusually large reduction may weigh on sentiment, although insider selling does not necessarily indicate a deteriorating business outlook. SEC insider transaction filing
• Negative Sentiment: EVP Craig C. Hopkinson sold 9,000 shares valued at roughly $437,000, cutting his holdings by 11.48%. EVP David Joseph Gaffin also sold 2,034 shares for about $99,000, reducing his position by 0.89%. Both executive transactions were conducted under pre-arranged Rule 10b5-1 plans, which limits their value as discretionary bearish signals. Craig Hopkinson SEC insider transaction filing David Gaffin SEC insider transaction filing

Insider Transactions at Alkermes

In related news, EVP Craig C. Hopkinson sold 9,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $51.51, for a total value of $463,590.00. Following the transaction, the executive vice president owned 73,389 shares in the company, valued at $3,780,267.39. This trade represents a 10.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nancy Lynn Md Snyderman sold 44,472 shares of Alkermes stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $50.35, for a total value of $2,239,165.20. Following the completion of the sale, the director owned 15,395 shares of the company’s stock, valued at approximately $775,138.25. The trade was a 74.28% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 79,574 shares of company stock worth $3,901,478. 4.59% of the stock is owned by insiders.

Alkermes Profile

Alkermes plc is a biopharmaceutical company focused on developing innovative medicines to address unmet needs in the central nervous system (CNS). The company applies its proprietary drug delivery technologies and therapeutic expertise to advance treatments for addiction, schizophrenia, bipolar I disorder and depression. Alkermes’ portfolio includes both commercial products and a pipeline of investigational therapies designed to improve patient outcomes and support long-term disease management.

Alkermes’ commercial franchise features several approved products.